News

This randomized, double-blinded, placebo-controlled study enrolled patients in the US with moderate-to-severe osteoarthritic pain. Following a titration period, patients were randomized to either twice-daily Remoxy (10-80 mg daily)

The trial will be conducted in two parts, both using an open-label, non-controlled design. Eligible patients will include adult patients with advanced newly diagnosed pancreatic cancer. Part A

It is expected that AP23573 will enter into Phase III clinical development for the treatment of metastatic sarcomas beginning this quarter. The agreement provides for an initial payment

The DSMB meets regularly every six months to review unblinded safety data from the two Phase III clinical trials. “The DSMB reviewed safety data of the approximately 3,000

Dr Liu Zhongyi, Lotus CEO and founder, said, “in April 2007, our company invested about $750,000 to develop injectable Ganbifu, which is primarily used for the treatment of

LCP-AtorFen will address three primary cardiovascular risk factors: low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglycerides (TG). The trial is designed as a double-blind,

YM says AeroLEF is a unique, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain. The company

“This agreement marks our first foray into Asia as we continue to establish sales channels in key markets around the world as part of the global commercialization program

The company said that, based on the current production schedule, which began on July 6, 2007, PurEffect infomercials will begin broadcasting in fall 2007. eFoodSafety.com expects sales revenue